Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Caladrius Bio (NQ: CLBS )

1.760 USD +0.050 (+2.92%)
Official Closing Price Updated: 7:59 PM EDT, Apr 9, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Caladrius Bio

< Previous 1 2 3 4 5 6 7 8 Next >
Caladrius Biosciences to Host Third Quarter 2018 Financial Results Conference Call on Thursday, November 8, 2018 at 4:30 p.m. ET
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and... 
From GlobeNewswire News Releases
46 Biggest Movers From Yesterday
Gainers Youngevity International, Inc. (NASDAQ: YGYI) surged 66.01 percent to close at $10.16 on Tuesday after falling 15.82 ... 
Tags ACRX XXII SFS
From Benzinga
Caladrius Biosciences to Participate in Upcoming October Conferences
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select... 
From GlobeNewswire News Releases
Danforth Advisors Names Robert Dickey IV Managing Director, Mid Atlantic Region
Danforth Advisors, LLC, specialists in accounting, finance support and strategy for life science and healthcare companies, today announced additional regional leadership and support with the... 
From GlobeNewswire News Releases
Caladrius Biosciences to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select... 
From GlobeNewswire News Releases
The Daily Biotech Pulse: Puma, CareDx Soar On Earnings, Corcept Plunges On Bottom-Line Miss
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week ... 
Tags CRNX News REGN
From Benzinga
Caladrius Biosciences Reports 2018 Second Quarter and First Six Months Financial Results
Conference call begins today at 4:30 p.m. Eastern time 
From GlobeNewswire News Releases
The Daily Biotech Pulse: Ampio Slides On Offering, Sangamo's Positive Trial Results, Insys Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week ... 
Tags News PULM KMPH
From Benzinga
Caladrius Biosciences to Host Second Quarter 2018 Financial Results Conference Call on Thursday, August 9, 2018 at 4:30 p.m. ET
Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and... 
From GlobeNewswire News Releases
Best Penny Stocks To Buy Now
The best penny stocks to buy now have significant upside potential and limited downside risk. Generally, stocks in new industries like the growing cannabis, marijuana, blockchain, or cryptocurrency... 
Tags self grpn kgc
From ETF Trends
38 Biggest Movers From Friday
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares climbed 68.61 percent to close at $4.62 on Friday after the company issued upbeat ... 
Tags Movers From Friday CALI CLPS
From Benzinga
How To Trade Gaps That Just Won't Go
I’m writing in the midst of a four-day green streak, which I am counting as a huge win after some of the recent red days ... 
Tags Education Warrior Trading Markets
From Benzinga
56 Biggest Movers From Yesterday
Gainers Ability Inc. (NASDAQ: ABIL) shares surged 110.65 percent to close at $4.55 on Thursday. AVROBIO, INC. (NASDAQ: AVRO) ... 
Tags BOXL RYTM XBIO
From Benzinga
Benzinga's Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week ... 
Tags MGTA Market News GKOS
From Benzinga
50 Biggest Movers From Yesterday
Gainers CLPS Incorporation (NASDAQ: CLPS) jumped 56.13 percent to close at $16.80 on Wednesday after the company released a letter ... 
Tags APEN UPL NBEV
From Benzinga
Benzinga's Daily Biotech Pulse: Sarepta's DMD Gene Therapy, Anika's Flunked Trial, Eidos To Commence Trading
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week ... 
Tags NVS ARRY SLDB
From Benzinga
28 Stocks Moving In Wednesday's Pre-Market Session
Gainers Naked Brand Group Inc (NASDAQ: NAKD) shares rose 169.2 percent to $4.28 in pre-market trading. Caladrius Biosciences Inc ... 
Tags SOL HJLI Energy
From Benzinga
10 Stocks To Watch For June 20, 2018
Some of the stocks that may grab investor focus today are: Wall Street expects Winnebago Industries, Inc. (NYSE: WGO) to report ... 
Tags Earnings CLBS WGO
From Benzinga
48 Biggest Movers From Yesterday
Gainers Astrotech Corporation (NASDAQ: ASTC) shares surged 217.44 percent to close at $6.1901 on Tuesday after the ... 
Tags AKCA HUYA CLWT
From Benzinga
7 Stocks Moving In Tuesday's After-Hours Session
Gainers Caladrius Biosciences Inc (NASDAQ: CLBS) shares are up 34 percent after announcing the company’s CD34+ cell therapy ... 
Tags After/Hours Center Movers ORCL
From Benzinga
Caladrius Receives FDA Regenerative Medicine Advanced Therapy Designation for CD34+ Cell Therapy for Treating Refractory Angina
Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and... 
From GlobeNewswire News Releases
23 Stocks Moving In Thursday's Pre-Market Session
Gainers Teligent, Inc. (NASDAQ: TLGT) shares rose 21.4 percent to $3.97 in pre-market trading following the FDA approval of ... 
Tags RENX CULP GOOD
From Benzinga
Caladrius Biosciences Sells Rights to Counter-Flow Centrifugation System to Hitachi Chemical Advanced Therapeutics Solutions
Sale of non-core asset brings $2.5 million in non-dilutive funding 
From GlobeNewswire News Releases
Caladrius Biosciences to Participate at the 15th International Symposium on Cardiovascular Regeneration and Repair
Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular... 
From GlobeNewswire News Releases
Caladrius Biosciences to Host First Quarter 2018 Financial Results Conference Call on Thursday, May 10, 2018 at 4:30 p.m. Eastern Time
Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology... 
From GlobeNewswire News Releases
BRIEF-Caladrius Biosciences Receives Sakigake Expedited Review Designation In Japan For CLBS12 For Treating Critical Limb Ischemia
* CALADRIUS BIOSCIENCES RECEIVES SAKIGAKE EXPEDITED REVIEW DESIGNATION IN JAPAN FOR CLBS12 FOR TREATING CRITICAL LIMB ISCHEMIA Source text for Eikon: Further company coverage: 
Tags companyNews
From Reuters: Company News
Caladrius Biosciences Receives SAKIGAKE Expedited Review Designation in Japan for CLBS12 for Treating Critical Limb Ischemia
Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology... 
From GlobeNewswire News Releases
Caladrius Biosciences to Present at The MicroCap Conference
Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular... 
From GlobeNewswire News Releases
Caladrius Biosciences to Host Fourth Quarter and Year End 2017 Financial Results Conference Call on Thursday, March 22, 2018 at 4:30 p.m. Eastern Time
Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular... 
From GlobeNewswire News Releases
BRIEF-Caladrius Biosciences Doses First Patient In Mid-Stage Critical Limb Ischemia Trial In Japan
* CALADRIUS BIOSCIENCES DOSES FIRST PATIENT WITH CLBS12 IN PHASE 2 CRITICAL LIMB ISCHEMIA TRIAL IN JAPAN Source text for Eikon: Further company coverage: 
Tags companyNews
From Reuters: Company News
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.